We are live on ! Find out more
RNAM

Avidity Biosciences

Delisted

RNAM was delisted on the 26th of February, 2026.

115 hedge funds and large institutions have $758M invested in Avidity Biosciences in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 18 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

173,100% more call options, than puts

Call options by funds: $3.46M | Put options by funds: $2K

852% more capital inflows, than outflows

Capital inflows: $80.5M | Capital outflows: $8.45M

280% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 5

139% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 18

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

13% more funds holding

Funds holding: 102 → 115 (+13)

5.78% more ownership

Funds ownership: 99.01% → 104.79% (+5.8%)

Holders
115
Holders Change
+13
Holders Change %
+12.75%
% of All Funds
1.93%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
19
Increased
43
Reduced
18
Closed
5
Calls
$3.46​M
Puts
$2​K
Net Calls
+$3.46​M
Net Calls Change
+$747​K

RNAM Hedge Fund Activity: Q2 2022 in Review

115 of the 5,961 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q2 2022, worth a combined $758M — down 13% from $873M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RNAM positions and 5 closed out — a net gain of 14 holders — while 43 added to existing stakes and 18 trimmed.

The largest buyer was Cowen and Company, opening a new position worth an estimated $33.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.52M.

  • 115 institutional investors held Avidity Biosciences (RNAM) as of Q2 2022, up from 102 in Q1 2022.
  • Funds reported $758M of Avidity Biosciences stock for Q2 2022, down 13% quarter-over-quarter.
  • 19 funds opened new Avidity Biosciences positions in Q2 2022 and 5 closed out, a net change of +14 holders.
  • The largest Avidity Biosciences buyer in Q2 2022 was Cowen and Company, an estimated $33.7M added.
  • The largest Avidity Biosciences seller in Q2 2022 was T. Rowe Price Associates, an estimated $1.52M sold.

Based on aggregated 13F filings for Q2 2022.